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Numerous mechanisms have been proposed to explain the anti-carcinogenic effects of Se, among them altered carcinogen metabolism. We inves-
tigated the effect of Se supplementation on activities of glutathione peroxidase (GPX), glutathione reductase (GR) and glutathione S-transferase
(GST) in different blood compartments, and expression of selected phase 1 and phase 2 genes in leucocytes (GPX1, g-glutamylcysteine ligase
catalytic subunit (GCLC), AP-1 transcription factor Fos-related antigen 1 (Fra1), NAD(P)H:quinone oxidoreductase (NQO1), and aryl hydro-
carbon receptor repressor (AhRR)). Healthy elderly Danes (n 105; age 71·3 (SD 4·26) years; 36 % reporting use of multivitamin/mineral sup-
plements) participated and were supplemented daily for 5 years with placebo, 100mg, 200mg or 300mg Se as Se-enriched yeast
(SelenoPrecisew). Blood samples were collected after 5 years of intervention. When all four groups were compared we found no effect of Se sup-
plementation on plasma GPX or GR, on erythrocyte GPX, GR or GST, or on thrombocyte GR or GST. We found increased thrombocyte GPX
activity at the two highest dosage levels in women only, but not in men. No effects on GPX1, NQO1 or AhRR gene expression were found.
When all Se-supplemented groups were pooled we found significant down regulation of the expression of some phase 2 genes (GCLC, Fra1).
A significant increase in AhRR gene expression with smoking was found but was independent of Se supplementation. Down regulation of
phase 2 genes could increase the risk of cancer. However, further studies are needed to establish whether the observed effect in leucocytes reflects
a similar expression pattern in target tissues.
Human nutrition: Selenium: Oxidative defence: Electrophile response elements
Se is an essential micronutrient that is incorporated specifi-
cally as selenocysteine into the active site of selenoproteins
(such as the glutathione peroxidases; GPX). Se as an antioxi-
dant helps to maintain intracellular redox balance, promoting a
reducing environment and thereby limiting oxidative damage
caused by free radicals. It has been suggested that Se intakes
above the level necessary to saturate selenoproteins can reduce
the risk of cancer. In the Nutritional Prevention of Cancer
Trial published in 1996, a daily supplement of 200mg Se, as
Se-enriched yeast, in patients with a history of basal cell or
squamous cell carcinoma of the skin showed a significant
increase in recurrence of skin cancer, but a significant
reduction in overall cancer risk, in risk of cancers with a
more severe prognosis, such as prostate, colorectal and lung
cancer, and consequently a decrease in total cancer mor-
tality(1 – 3). The strongest effect was found in individuals
with a baseline plasma Se (pSe) level below 106mg/l, while
no protective effect was found in the upper tertile(4). Most
of the participants in the Nutritional Prevention of Cancer
Trial had initial Se intakes above the level required to saturate
selenoproteins, indicating that the observed effects of Se are
not limited to antioxidant functions through selenoproteins.
Based on results from numerous rodent cancer models, it has
also been proposed that alterations in carcinogen metabolism
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resulting in increased enzymic defence play a role in the
cancer-protective effect of Se. But results are far from consist-
ent and may vary with choice of animal model, choice of car-
cinogen, Se source, Se dosage level and tissue studied(5 – 7).
Se deficiency has been associated with a decrease in GPX
activity as well as in mRNA levels(8). Besides affecting
expression and activity of selenoproteins, Se is also involved
in the regulation of other gene products. Se supplementation
has been reported to increase blood glutathione (GSH)
levels, indicating reduced oxidative stress(9). Glutathione
reductase (GR) is the principal enzyme maintaining GSH in
its reduced form. GSH is also a cofactor for GPX and is
necessary for GSH conjugation by glutathione S-transferases
(GST). g-Glutamylcysteine ligase (GCL) composed of a cata-
lytic (GCLC) and a modulatory (GCLM) subunit is the first
step in the de novo synthesis of GSH(10,11). Common for
GCLC and GCLM and other genes encoding phase 2 detoxify-
ing enzymes, including NAD(P)H:quinone oxidoreductase
(NQO1) and GST, is the presence of electrophile response
elements (EpRE) in the promoter regions (TGACNNNGC),
which mediate the transcriptional up regulation in response
to a variety of inducing agents(12). The AP-1 transcription
factor Fos-related antigen 1 (Fra1) may contain an EpRE in
its promoter region(13) and is able to down regulate NQO1
and GCLC gene expression(14,15) through embedded AP-1
sites (TGACTCA)(16,17). Se could induce or repress these
gene responses through EpRE.
Up regulation of genes encoding phase 1 xenobiotic meta-
bolising enzymes in the liver has been reported in Se-deficient
mice(18). Some xenobiotics interact with the aryl hydrocarbon
receptor (AhR) and transactivate target genes such as cyto-
chrome P450 through the xenobiotic response element
(XRE). The aryl hydrocarbon receptor repressor (AhRR) regu-
lates AhR function by a negative feed-back mechanism,
thereby down regulating genes that are regulated by AhR(19).
The promoter region of AhRR contains 3 XRE binding sites,
and could potentially be affected by Se supplementation(20).
In Denmark, the average daily dietary Se intake (excluding
supplements) is low compared with other countries(21), being
42mg/d for men and 33mg/d for women according to the
latest survey(22). But Se supplementation through multivitamin
and mineral supplements is very common, adding on average
25mg. We assumed that a population like the Danish, with
relatively low Se intakes, would be appropriate for studying
the biological effects of Se supplementation.
The aim of the present study was to investigate whether the
dietary Se intake of elderly Danes is sufficient to obtain sat-
uration of GPX expression in different blood compartments,
and whether increased Se intake will affect gene expression
and activity of selected phase 2 enzymes and transcription
factors containing EpRE or XRE in their promoter, as has
been reported in animal studies. We therefore investigated
whether a daily Se supplement of 100, 200 or 300mg as
Se-enriched yeast for 5 years would increase activities of
GPX, GR and GST in erythrocytes, plasma or thrombocytes,
and modulate gene expression of Fra1, GCLC, GPX1, AhRR
and NQO1 in leucocytes. The use of three dosage levels
enabled us to look closer at dose–response relationships.
We also investigated the overall effect of Se supplementation
by pooling the supplemented groups and testing them against
the placebo group.
Materials and methods
Subjects and study design
In 1999, a cohort of 500 men and women was established in
Denmark. Participants were recruited from the county of
Funen, were between the ages of 60 and 74 years, had no pre-
vious cancer diagnosed, had no severe or life-threatening dis-
eases and a daily intake of Se supplementation not exceeding
50mg (a typical multivitamin/mineral supplement sold in Den-
mark contains 40–50mg inorganic Se). A 1-month run-in
period where subjects were supplemented with placebo tablets
ensured exclusion of participants who were not compliant. The
study was a randomised, double-blinded, placebo-controlled
intervention experiment with a parallel design. At recruitment
each participant was randomised to one of four groups, a pla-
cebo group and three dosage levels: 100, 200 or 300mg Se as
Se-enriched yeast (SelenoPrecisew; Pharma Nord, Vejle, Den-
mark). The Se-enriched yeast has previously been reported to
consist of about 81 % selenomethionine in the fraction liber-
ated by proteolysis(23). At study entry and at 6, 12, 18, 24,
36 and 60 months the participants visited the centre to
donate a blood sample, collect tablets for the following
period and answering questions concerning compliance and
side effects, such as garlic breath, hair loss and nail brittleness.
Based on counting of returned pill packets after years 1, 2 and
3, compliance was .96 %. No serious adverse effects were
reported and there was no correlation to Se dose (details
will be published elsewhere). The supplementation lasted 5
years. The last blood samples were collected after 5 years of
supplementation and the present study was performed on a
random sub-sample of 105 participants, selected consecutively
among those who attended the centre for the terminal visit
within a certain time period. All participants gave oral and
written consent according to the second Helsinki declaration.
The study was approved by the regional ethical committees
of Vejle and Funen (journal no. 19980186).
Blood sampling and storage
After supine rest for 10 min, blood samples were collected
from non-fasting participants in 10 ml EDTA-coated tubes
(Becton Dickinson, Franklin Lakes, NJ, USA), and centri-
fuged for 15 min (150 g; room temperature). Thrombocytes
were isolated from the thrombocyte-rich plasma by centrifu-
gation (1500 g; room temperature; 5 min). The thrombocyte
pellet was washed twice in 0·9 % NaCl and re-suspended in
0·5 ml 0·9 % NaCl. Erythrocytes and buffy coat were isolated
by centrifugation (1500 g; room temperature; 10 min). The
buffy coat was re-suspended in RLT buffer (QIAgen, Bal-
lerup, Denmark). Erythrocytes were lysed by adding an
equal amount of MilliQ water to the tube. Plasma, thrombo-
cytes, buffy coat and erythrocytes were stored at 2808C.
Plasma selenium status
pSe concentration was determined as previously described
using an ELAN 6100 ICP-DRC-MS (PerkinElmer SCIEX,
Concord, ON, Canada) equipped with an AS-91 autosampler
(PerkinElmer, Norwalk, CT, USA)(24). For every fifteen
unknown plasma samples one duplicate sample, one field
blank, one certified reference sample and three Se (10mg/l)
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standard solutions were included. The latter were used to cor-
rect for instrumental drift. Based on the determination of field
blanks the limit of detection was estimated at 0·1mg Se/l and
the uncertainty was estimated from the differences between
double determinations at 2·1 % relative SD. The accuracy
was determined by including a reference sample with a
known content of 73 (SD 8)mg/l (Seronorm Serum; Nycomed
Pharma Diagnostics, Oslo, Norway). We found an Se concen-
tration of 77 (SD 6)mg/l in this sample.
Defence enzyme activities (glutathione peroxidase, glutathione
reductase and glutathione S-transferase)
Erythrocyte, plasma and thrombocyte GPX and GR activities
were determined spectrophotometrically on a Cobas Mira
analyser (F. Hoffmann-La Roche Ltd, Basel, Switzerland)
according to Wheeler et al. (25). t-Butyl hydroperoxide was
used as substrate for GPX. GST activity was measured in
thrombocytes and erythrocytes as previously described(26).
Enzyme activities measured in erythrocyte lysates were
related to the amount of Hb in the sample. Enzyme activi-
ties determined in thrombocytes and plasma were related
to the amount of total protein. Hb and total protein contents
were determined using commercially available kits (catalo-
gue no. HG 980, Randox, Crumlin, Co. Antrim, UK; catalo-
gue no. A11A01669, ABX Diagnostics, Montpellier, France,
respectively). Control samples (erythrocytes, plasma and
thrombocytes) were included for every tenth sample ana-
lysed. Inter- and intraday variations for the control samples
were ,7 %.
RNA isolation and cDNA synthesis
Total RNA was extracted from the buffy coat using the
QIAampw RNA blood mini kit (QIAgen, Ballerup, Denmark).
The concentration and purity of the RNA was determined
by measuring the absorbance at 260 and 280 nm using the
NanoDropw ND-1000 UV-Vis spectrophotometer (NanoDrop
Technologies, Wilmington, DE, USA). A ratio (A260:A280)
of .1·8 indicated suitable purity. First-strand cDNA was
synthesised using 500 ng total RNA in a final volume of 10ml
with Random Hexamer primer and SuperscriptTM II Rnase
H-RT according to the manufacturers (Invitrogen, Taastrup,
Denmark).
Primer and probe design
Oligonucleotide primers and TaqManw probes were
designed with Primer Express software v. 1.5 (Applied Bio-
systems, Stockholm, Sweden), based on sequences from the
Genbank database (Table 1). Genomic DNA amplification
was excluded whenever possible by designing intron span-
ning probes.
Leucocyte mRNA quantification of Fos-related antigen 1,
glutathione peroxidase 1, g-glutamylcysteine ligase catalytic
subunit, NAD(P)H:quinone oxidoreductase and aryl hydro-
carbon receptor repressor. Real-time PCR of the five genes
was performed on an ABI PRISMw 7900HT Sequence Detec-
tion System (Applied Biosystems, Stockholm, Sweden). The
PCR reaction was determined in a 20ml final volume adding
2 ng cDNA, using TaqManw Universal PCR Master Mix
(Applied Biosystems, Stockholm, Sweden). For each target
gene, the probe concentration was 0·3mM and the primer con-
centrations for the detection of GCLC, AhRR and NQO1 genes
were 0·3mM, 0·5mM for GPX1, and 0·9mM for Fra1. The con-
stitutively expressed 18S rRNA primer/probe-set (Applied
Biosystems, Stockholm, Sweden) was selected as an endogen-
ous control to correct for potential variation in RNA loading
or efficiency of the amplification reaction and used as rec-
ommended by the manufacturers.
The PCR amplification was performed in ninety-six-well
plates in triplicates using the following cycling protocol:
508C for 2 min, 958C for 10 min, forty-five cycles at 958C
for 15 s and 608C for 1 min. To confirm equal amplification
efficiencies, we used the criterion of a regression slope of
less than 0·1 for each target gene normalised to 18S rRNA.
This confirms that we could use the comparative cycle
threshold (Ct) method for the relative quantification of target
without running standard curves on the same plate (data not
shown). Relative changes in gene expression were calculated
Table 1. Oligonucleotides and TaqManw fluorogenic probes
Gene Genbank Primer/probe Sequence 50 –30
GPX1 AY327818 Sense CCCGTGCAACCAGTTTGG
Antisense TGAGGGAATTCAGAATCTCTTCGT
TaqManw probe 6-FAM-CATCAGGAGAACGCC-MGB
GCLC NM_001498 Sense CGGCACAAGGACGTTCTCA
Antisense ACCGGACTTTTTTATTTTCATGATCA
TaqManw probe 6-FAM-CGATGAGGTGGAATAC-MGB
NQO1 NM_000903 Sense CTTCAATCCCATCATTTCCAGAA
Antisense GACTCGGCAGGATACTGAAAGTTC
TaqManw probe 6-FAM-CATCACAGGTAAACTGAAG-MGB
Fra1 NM_005438 Sense GCCGCCCTGTACCTTGTATC
Antisense CAGTGCCTCAGGTTCAAGCA
TaqManw probe 6-FAM-CTTTCCCCAGGGCCT-MGB
AhRR NM_020731 Sense GAATCGGAACTGCATGGAAAA
Antisense CCAAAACGCCGCTCTCTCT
TaqManw probe 6-FAM-CAATTACTCAGCAGGAAGG-MGB
GPX1, glutathione peroxidase 1; 6-FAM, 6-carboxyfluorescein; MGB, minor groove binding; GCLC, g-glutamylcysteine ligase catalytic subunit;
NQO1, NAD(P)H quinone oxidoreductase 1; Fra1, FOS-like antigen 1; AhRR, aryl-hydrocarbon receptor repressor.
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by the DDCt method (Applied Biosystems, 2001, User Bulle-
tin no. 2, ABI PRISM 7700 Sequence Detection System,
Foster City, CA, USA). Inter-plate variation for a control
sample (n 27) was ,2 % for all genes.
Statistical analysis
Treatment effects were analysed with the general linear
model, with sex, smoking and their interactions with treatment
included in the model. Weight was significantly higher among
men than women, and was therefore included in the model as
a covariate. Since a large proportion of subjects reported
taking multivitamin/mineral supplements, use of additional
supplements was included in the statistical analyses as a cov-
ariate. For comparison of two groups, t tests were used (pla-
cebo against pooled Se-supplemented groups). Data that
could not meet the criteria of variance homogeneity and
normal distribution after log transformation were analysed
by non-parametric tests (Kruskal–Wallis H test or Mann–
Whitney U test). Group differences for categorical data were
analysed using the x2 test. For all tests a P value less than
0·05 was considered statistically significant. Pearson corre-
lations were used to identify correlating variables. All statisti-
cal analyses were performed using SAS (SAS Institute, Cary,
NC, USA).
Results
Study population
Baseline characteristics for the study participants are pre-
sented in Table 2 as mean values and standard deviations
(age, weight) or as percentages (smoking status, sex). The par-
ticipants were predominantly non-smokers and in the selected
sub-sample for the present study women assigned to the high-
est dosage level were older compared with women in the
lowest and medium dosage groups (Table 2). Women had sig-
nificantly lower body weight compared with men (P,0·001).
Otherwise, there were no statistically significant differences in
baseline characteristics between the groups.
Records of the use of multivitamin/mineral supplements
among the participants (registered at time of final blood
sampling, year 5) indicate that on average 36 % took addi-
tional supplements (as ordinary multivitamin/mineral tablets);
however, the percentage of supplement users was about
twice as high among participants from the highest dosage
group compared with the rest (Table 2). No participants reported
use of specific Se supplements.
Compliance
pSe concentration was measured to test for compliance. Se
status increased linearly (R 2 0·98; P,0·0001) with increas-
ing Se intake (Table 3), indicating a high degree of compli-
ance. Smoking status did not influence pSe (P.0·05) (data
not shown).
Enzyme activities
There was a statistically significant effect on thrombocyte
GPX activity (tGPX) (P¼0·003), with a statistically significant
treatment £ sex interaction (P¼0·008). When subjects were
stratified according to sex, we found an effect of Se supplemen-
tation on tGPX activity in women only (Pwomen ¼ 0·006)
(Table 3). tGPX activity was significantly increased in groups
supplemented with 200 or 300mg/d (Pplacebo2200mg ¼ 0·001;
Pplacebo2300mg ¼ 0·008), while there was a tendency towards
increased tGPX activity at the lowest dosage level (Pplacebo2100
mg ¼ 0·084) compared with placebo. We found no statistically
significant difference in tGPX between the two highest dosage
levels (P200mg – 300mg ¼ 0·688). No effect of Se supplemen-
tation on tGPX was observed in men (Pmen ¼ 0·401). We
found no effect of Se supplementation on plasma GR or
GPX, on erythrocyte GR, GPX or GST, or on GR or GST
measured in thrombocytes (Table 3). We found no interaction
with smoking on any of the activities.
When all supplemented groups were pooled and tested
against the placebo group, only tGPX was significantly
increased with Se supplementation (P¼0·027) and, again,
only women responded (Pwomen ¼ 0·004; Pmen ¼ 0·596). pSe
correlated with plasma GPX activity (P¼0·046; r 0·212) but
not tGPX (P¼0·106) or erythrocyte GPX (P¼0·162).
Gene expression
Se supplementation did not affect gene expression of GPX1,
Fra1, GCLC, NQO1 or AhRR in leucocytes (Table 4), when
all groups were tested against each other. There was a large
Table 2. Baseline characteristics of the study participants
(Mean values and standard deviations or percentages)
Placebo 100mg/d 200mg/d 300mg/d
n Mean SD n Mean SD n Mean SD n Mean SD
Age (years) 28 70·4 3·8 27 70·3 3·6 23 71·6 4·2 27 73·0 5·0
Weight (kg)
All subjects 28 78·5 12 27 73·1 12 23 75·6 15 27 80·6 13
Men 13 83·3 8·2 12 80·9 9·1 9 87·7 10 15 81·7 11
Women* 15 74·3 13 15 67·0 9·4 14 67·7 12 12 79·2† 14
Smokers (%) 28 36 27 22 23 22 27 19
Supplement users (%) 28 29 27 26 23 35 27 56
Males (%) 28 46 27 44 23 39 27 56
*Compared with men, women had significantly lower body weight (P,0·001; ANOVA).
†Highest dosage group was significantly different from lowest dosage group (100mg/d) and medium dosage group (200mg/d) (P,0·05; ANOVA).
Selenium and oxidative defence 1193
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
http://dx.doi.org/10.1017/S0007114507882948
Downloaded from https:/www.cambridge.org/core. Open University Libraryy, on 09 Jan 2017 at 17:33:09, subject to the Cambridge Core terms of use, available at https:/www.cambridge.org/core/terms.
inter-individual variation in the expression of the transcription
factors Fra1 and AhRR, especially in the placebo group (Table 4).
When the Se-supplemented groups were pooled and tested
against placebo, we found a statistically significant decrease
in expression of Fra1 and GCLC (P¼0·019 and P¼0·042,
respectively) and a tendency towards a decreased expression
of NQO1 (P¼0·067) and AhRR (P¼0·085). There was no
effect of Se on GPX1 (P¼0·281). AhRR was the only gene
Table 3. Effect of selenium supplementation on plasma selenium and activities of glutathione peroxidase (GPX), glutathione reductase (GR) and gluta-
thione S-transferase (GST) measured in plasma, erythrocytes or thrombocytes
(Medians and 10th and 90th percentiles and means and standard deviations)
Placebo 100mg/d 200mg/d 300mg/d
Plasma
Se (mg/l) All n 24 22 20 23
Median 93·0 159* 207* 242*
10th, 90th percentiles 77·3, 105 134, 217 177, 266 203, 341
Mean 92 165* 221* 260*
SD 11·2 31·6 42·3 59·7
GPX (units per g protein) All n 28 27 23 27
Median 14·0 15·0 14·2 14·4
10th, 90th percentiles 11·0, 15·9 12·4, 17·2 12·0, 17·4 12·6, 16·9
Mean 13·7 14·7 14·5 14·5
SD 1·95 2·35 2·31 2·10
GR (units per g protein) All n 28 27 23 27
Median 0·85 0·85 0·88 0·85
10th, 90th percentiles 0·72, 1·12 0·71, 1·01 0·65, 1·06 0·74, 0·99
Mean 0·91 0·85 0·87 0·87
SD 0·26 0·12 0·17 0·13
Erythrocytes (units per g Hb)
GPX All n 28 27 23 27
Median 92·8 99·5 96·5 99·4
10th, 90th percentiles 69·3, 110 66·0, 131 78·2, 135 75·0, 124
Mean 92·7 98·8 104 98·8
SD 18·0 24·9 28·1 19·0
GR All n 28 27 23 27
Median 11·5 11·7 11·5 12·4
10th, 90th percentiles 9·49, 13·4 9·60, 13·0 10·1, 12·9 10·2, 14·1
Mean 11·4 11·5 11·4 12·3
SD 1·6 1·5 1·1 1·5
GST All n 28 27 23 27
Median 8·25 7·72 8·05 8·40
10th, 90th percentiles 5·20, 12·1 5·55, 10·7 4·15, 10·7 6·08, 12·0
Mean 8·42 8·00 7·66 8·86
SD 2·9 2·2 2·9 3·2
Thrombocytes (units per g protein)
GPX All n 28 27 23 25
Median 202 224 300 315
10th, 90th percentiles 80·3, 393 129, 431 84·8, 590 125, 543
Mean 221 251 323 320
SD 146 113 217 174
Men n 13 12 9 14
Median 224 196 138 208
10th, 90th percentiles 75·8, 371 130, 343 66·3, 473 86·8, 515
Mean 218 224 222 283
SD 126 96·1 194 183
Women n 15 15 14 11
Median 155 251 312* 336*
10th, 90th percentiles 90·8, 427 130, 441 214, 670 187, 553
Mean 225 274 389* 368*
SD 165 124 212 157
GR All n 27 27 22 25
Median 47·9 41·6 49·0 44·9
10th, 90th percentiles 28·8, 65·9 20·9, 54·5 20·1, 59·9 21·5, 70·6
Mean 47·6 40·1 44·1 45·8
SD 16·4 15·0 14·8 17·7
GST All n 27 27 22 25
Median 110 69·5 107 73·8
10th, 90th percentiles 42·8, 191 33·1, 168 32·9, 233 33·9, 164
Mean 110 95·4 128 92·2
SD 57·2 58·3 104 59·5
*Significantly different from placebo group (P,0·05; ANOVA).
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expression marker influenced by smoking status. Smoking
increased the expression of AhRR (P¼0·0001) (Fig. 1), an
effect that was independent of Se supplementation.
Discussion
The anti-carcinogenic effects of Se have been linked to
increased expression of protective enzymes. In the
present study, we investigated the effect of 5 years of Se sup-
plementation on the activity and gene expression of selected
selenoproteins and genes involved in carcinogen metabolism.
The pSe concentration was determined to test for compliance
and we found a statistically significant increase in pSe with
increasing Se supplement intake. It has previously been
shown in numerous studies that pGPX and eGPX activities
increase with Se intake, and that the increase reaches a plateau
at intakes corresponding to pSe concentrations of about
70–90mg/l and higher(27,28). In the present study pSe concen-
trations in the placebo group were between 71 and 111mg/l
with a mean of 92mg/l. If we assume that the pSe in the control
group is representative of the mean Se status in the participants
before entry into the study, the lack of effect on pGPX and
eGPX activities could be explained by these high baseline
values, indicating that GPX is saturated in erythrocytes and
plasma. We found a statistically significant increase in tGPX
activity with Se supplementation, using Se-enriched yeast
which consists primarily of the organic Se compound seleno-
methionine(23). A sub-group analysis showed that the effect
of Se was sex specific. Se supplementation only affected
tGPX activity in women, and only at the two highest dosage
levels. The responses at these two levels were not statistically
different, suggesting that tGPX activity is saturated at pSe
concentrations between 165 and 221mg/l (means of the two
groups). This is a bit higher than previously reported
where tGPX activity plateaued at pSe concentrations
,150mg/l(27 – 30). tGPX activity has been reported to saturate
at higher pSe concentrations compared with eGPX and
pGPX(31), which could explain the observed positive effect
on GPX activity in thrombocytes. We are not aware of other
studies reporting this sex-specific difference in tGPX activity
in response to Se supplementation, and we cannot exclude
that a similar effect would have been observed in men, had
Table 4. Effect of selenium supplementation on glutathione peroxidase 1 (GPX1), g-glutamylcysteine ligase catalytic subunit
(GCLC), NAD(P)H quinone oxidoreductase 1 (NQO1), FOS-like antigen 1 (Fra1) and aryl-hydrocarbon receptor repressor (AhRR)
gene expression normalised to 18S rRNA
(Medians and 10th and 90th percentiles and means and standard deviations)
Placebo 100mg/d 200mg/d 300mg/d
GPX1 n 27 26 23 26
Median 0·90 0·88 0·82 0·86
10th, 90th percentiles 0·55, 1·54 0·55, 1·30 0·71, 1·34 0·59, 1·41
Mean 1·05 0·91 0·95 0·91
SD 0·58 0·31 0·33 0·34
GCLC n 27 26 23 26
Median 0·98 0·75 0·86 0·75
10th, 90th percentiles 0·62, 1·59 0·47, 1·08 0·49, 1·37 0·57, 1·42
Mean 1·02 0·81 0·88 0·93
SD 0·39 0·3 0·38 0·55
NQO1 n 27 26 23 26
Median 0·98 0·74 0·81 0·84
10th, 90th percentiles 0·52, 1·59 0·50, 1·13 0·56, 1·10 0·49, 1·33
Mean 1·05 0·82 0·86 0·91
SD 0·54 0·42 0·34 0·41
Fra1 n 27 26 23 26
Median 1·08 0·66 0·44 0·53
10th, 90th percentiles 0·25, 2·85 0·11, 1·77 0·13, 1·34 0·12, 2·18
Mean 1·8 0·94 0·83 1·0
SD 3·0 1·14 1·19 1·36
AhRR n 27 26 23 26
Median 0·69 0·71 0·65 0·78
10th, 90th percentiles 0·38, 4·36 0·27, 1·86 0·21, 1·58 0·22, 1·96
Mean 1·82 1·0 1·07 1·22
SD 2·39 0·93 1·56 2·05
Fig. 1. Effect of smoking on gene expression of aryl hydrocarbon receptor
repressor (AhRR) relative to the mean expression in the placebo group.
Values are means, with standard deviations represented by vertical bars.
Participants are sub-divided according to number of cigarettes smoked per d:
0 (n 77); 1–5 (n 8); 6–19 (n 11); þ20 (n 6). Pipe and cigar smokers are
placed in the group with smokers of 1–5 cigarettes per d. *Mean value is
significantly different from that of non-smokers (P,0·05; Kruskal–Wallis).
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the number of participants been higher. Although not statisti-
cally significant, we note that GPX activity in all blood frac-
tions increased with Se supplementation. In the present
study, five years of Se supplementation did not affect GR
activity in plasma, erythrocytes or thrombocytes, or GST
activity in erythrocytes or thrombocytes.
Large inter-individual differences in response to Se sup-
plementation have previously been reported(32). Brown et al.
found that the lower the baseline activity, the greater was
the increase in response to Se supplementation. Thus it is
possible that we would have seen effects of Se supplemen-
tation on GPX activity in erythrocytes and plasma if we had
had baseline measurements available, thereby allowing us to
investigate the individual responses, at least in individuals
having low baseline levels.
GPX activity was measured in three different blood com-
partments, and only pGPX correlated weakly with pSe con-
centration. Ne`ve et al. have previously reported significant
correlations between pSe and pGPX and tGPX activities(31)
but we were not able to show any correlations between pSe
and eGPX or tGPX activity. We did not measure Se status
in erythrocytes or thrombocytes and it is possible that Se is
channelled differently into various blood compartments as
GPX synthesis is requested.
Smoking has been reported to decrease Se status and GPX
activity(33,34). We found no interactions with smoking. One
possible explanation could be that the group of smokers in
the present study was much smaller than the group of non-
smokers, and individual smokers were very different regarding
smoking habits. Some participants smoked very rarely while
others smoked every day.
It has been hypothesised that Se at pharmacological doses
would influence expression of phase 1 and phase 2 genes con-
taining XRE or EpRE in their promoters(7). We found no
dose–response relationship on expression of AhRR, GPX1,
GCLC, NQO1 or Fra1 in leucocytes. Pooling the Se groups
and testing them against the placebo group showed decreased
expression of Fra1, GCLC and NQO1, although the latter did
not reach statistical significance. Fra1 has been reported to
down regulate GCLC and NQO1 (14,15). If this were the case
in the present study, we would have expected to see an up
regulation of Fra1. Instead we found the opposite. This may
indicate that Fra1 is not involved in the observed down regu-
lation of GCLC and NQO1. We found increased AhRR gene
expression with smoking. Cigarette smoke contains carcino-
gens such as polycyclic aromatic hydrocarbons that are
metabolised by cytochrome P450 enzymes. Therefore AhRR
is co-induced with cytochrome P450 enzymes via XRE(35).
Whether increased AhRR expression in leucocytes is a
marker for smoking needs further investigation. None of the
other genes were transcribed differently as a function of
smoking and there were no significant interactions between
smoking and pSe on gene transcription.
Gene expression of phase 2 enzymes has been shown to
vary with the studied organ, and results on whether blood
expression profiles can be used as surrogate markers of
organ expression are conflicting(36,37). Finnstrom et al. found
no correlation between blood and liver mRNA expression pat-
terns of cytochrome P450 genes, but they noted that genes that
were highly expressed in the liver at the same time could be
expressed at lowered levels in the blood(38). Rauchy et al.
on the other hand found good correlation(39). Results are
inconclusive and further studies as to whether a blood
sample can be used to determine the expression profile in
target organs are needed. Furthermore, leucocytes are a mix-
ture of many different cell types, and it has been shown that
the profile of these cells vary from subject to subject based
on cell type counts(37). There might therefore be different
expression profiles among different leucocyte cell types.
Decreased gene expression of phase 2 enzymes in the blood
compartment reported here may thus reflect changed compo-
sition of the leucocyte cell pool. It may also reflect altered
expression in other tissues. In a study in transgenic mice con-
taining a GCLC-luc construct, luciferase activity increased in
brain and muscle but decreased in liver following treatments
with berry extracts or ellagic acid(36), indicating that complex
up and down regulation may take place in different tissues as a
response to redox active dietary components. We speculate
that Se compounds may elicit similar complex actions in
different tissues leading to an overall down regulation of
EpRE-regulated genes in blood leucocytes.
We conclude that Se supplementation affects tGPX activity
differently in men and women. Se status in healthy elderly
Danish women is insufficient to obtain saturation of tGPX
activity and higher Se intake might increase oxidative defence
in this blood compartment. The present results indicate that Se
supplementation can down regulate leucocyte genes having
EpRE in their promoter and that Fra1 does not seem to be
involved in down regulation of GCLC and NQO1 with Se.
Decreased expression of EpRE-regulated genes could poten-
tially increase the risk of cancer. However, further studies
are needed to establish whether this down regulation in leuco-
cytes reflects a similar expression pattern in other tissues.
Acknowledgements
We thank all those who volunteered for the study, Vibeke
Kegel, Marianne Hansen, Geert Eisensee and her staff for
excellent technical support, and Asta Christiansen and
Hanne Hansen for their dedicated handling of the participants
in the study. The present study was financially supported by a
grant from the Danish Ministry of the Interior and Health,
Research Centre for Environmental Health Fund.
The authors’ responsibilities were as follows: S. C., K. O.
and S. M. designed the original trial; L. O. D. designed the
present sub-study; L. O. D. and E. H. L. obtained funding;
S. C. supervised blood sample collection; B. N. K. was
responsible for gene expression analyses; E. H. L. was respon-
sible for Se analyses; G. R. H. was responsible for enzyme
assays, undertook the statistical analyses and wrote the first
draft of the manuscript; K. O. and L. O. D. provided statistical
support. All authors approved the final manuscript. All authors
declared that they had no conflict of interest.
References
1. Clark LC, Combs GF Jr, Turnbull BW, et al. (1996) Effects of
selenium supplementation for cancer prevention in patients with
carcinoma of the skin. A randomized controlled trial. Nutritional
Prevention of Cancer Study Group. JAMA 276, 1957–1963.
G. Ravn-Haren et al.1196
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
http://dx.doi.org/10.1017/S0007114507882948
Downloaded from https:/www.cambridge.org/core. Open University Libraryy, on 09 Jan 2017 at 17:33:09, subject to the Cambridge Core terms of use, available at https:/www.cambridge.org/core/terms.
2. Clark LC, Dalkin B, Krongrad A, et al. (1998) Decreased inci-
dence of prostate cancer with selenium supplementation: results
of a double-blind cancer prevention trial. Br J Urol 81,
730–734.
3. Duffield-Lillico AJ, Slate EH, Reid ME, et al. (2003) Selenium
supplementation and secondary prevention of nonmelanoma
skin cancer in a randomized trial. J Natl Cancer Inst 95,
1477–1481.
4. Duffield-Lillico AJ, Reid ME, Turnbull BW, Combs GF Jr,
Slate EH, Fischbach LA, Marshall JR & Clark LC (2002) Base-
line characteristics and the effect of selenium supplementation
on cancer incidence in a randomized clinical trial: a summary
report of the Nutritional Prevention of Cancer Trial. Cancer
Epidemiol Biomarkers Prev 11, 630–639.
5. Combs GF Jr & Gray WP (1998) Chemopreventive agents: sel-
enium. Pharmacol Ther 79, 179–192.
6. Whanger PD (2004) Selenium and its relationship to cancer: an
update. Br J Nutr 91, 11–28.
7. El-Bayoumy K & Sinha R (2005) Molecular chemoprevention
by selenium: a genomic approach. Mutat Res 591, 224–236.
8. Rao L, Puschner B & Prolla TA (2001) Gene expression profil-
ing of low selenium status in the mouse intestine: transcriptional
activation of genes linked to DNA damage, cell cycle control
and oxidative stress. J Nutr 131, 3175–3181.
9. El-Bayoumy K, Richie JP Jr, Boyiri T, Komninou D, Prokopc-
zyk B, Trushin N, Kleinman W, Cox J, Pittman B & Colosimo S
(2002) Influence of selenium-enriched yeast supplementation
on biomarkers of oxidative damage and hormone status in
healthy adult males: a clinical pilot study. Cancer Epidemiol
Biomarkers Prev 11, 1459–1465.
10. Gipp JJ, Chang C & Mulcahy RT (1992) Cloning and nucleotide
sequence of a full-length cDNA for human liver g-glutamylcys-
teine synthetase. Biochem Biophys Res Commun 185, 29–35.
11. Gipp JJ, Bailey HH & Mulcahy RT (1995) Cloning and
sequencing of the cDNA for the light subunit of human liver
g-glutamylcysteine synthetase and relative mRNA levels for
heavy and light subunits in human normal tissues. Biochem
Biophys Res Commun 206, 584–589.
12. Chen C & Kong AN (2004) Dietary chemopreventive com-
pounds and ARE/EpRE signaling. Free Radic Biol Med 36,
1505–1516.
13. Yoshioka K, Deng T, Cavigelli M & Karin M (1995) Antitumor
promotion by phenolic antioxidants: inhibition of AP-1 activity
through induction of Fra expression. Proc Natl Acad Sci U S A
92, 4972–4976.
14. Venugopal R & Jaiswal AK (1996) Nrf1 and Nrf2 positively
and c-Fos and Fra1 negatively regulate the human antioxidant
response element-mediated expression of NAD(P)H:quinone
oxidoreductase1 gene. Proc Natl Acad Sci U S A 93,
14960–14965.
15. Jardine H, MacNee W, Donaldson K & Rahman I (2002)
Molecular mechanism of transforming growth factor (TGF)-
b1-induced glutathione depletion in alveolar epithelial cells.
Involvement of AP-1/ARE and Fra-1. J Biol Chem 277,
21158–21166.
16. Li Y & Jaiswal AK (1992) Regulation of human NAD(P)H:qui-
none oxidoreductase gene. Role of AP1 binding site contained
within human antioxidant response element. J Biol Chem 267,
15097–15104.
17. Mulcahy RT & Gipp JJ (1995) Identification of a putative anti-
oxidant response element in the 50-flanking region of the human
g-glutamylcysteine synthetase heavy subunit gene. Biochem
Biophys Res Commun 209, 227–233.
18. Reiter R & Wendel A (1984) Selenium and drug metabolism –
II. Independence of glutathione peroxidase and reversibility of
hepatic enzyme modulations in deficient mice. Biochem Phar-
macol 33, 1923–1928.
19. Mimura J, Ema M, Sogawa K & Fujii-Kuriyama Y (1999)
Identification of a novel mechanism of regulation of Ah
(dioxin) receptor function. Genes Dev 13, 20–25.
20. Cauchi S, Stucker I, Cenee S, Kremers P, Beaune P & Massaad-
Massade L (2003) Structure and polymorphisms of human aryl
hydrocarbon receptor repressor (AhRR) gene in a French popu-
lation: relationship with CYP1A1 inducibility and lung cancer.
Pharmacogenetics 13, 339–347.
21. Rayman MP (2000) The importance of selenium to human
health. Lancet 356, 233–241.
22. Lyhne N, Christensen T, Groth MV, Fagt S, Biltoft-Jensen A,
Hartkopp H, Hinsch H-J, Matthiessen J, Møller A, Saxholt E
& Trolle E (2005) Danskernes Kostvaner 2000–2002. Hovedre-
sultater (Dietary Habits in Denmark 2000–2002. Main Results).
Søborg, Denmark: Danish Institute for Food and Veterinary
Research.
23. Larsen EH, Hansen M, Paulin H, Moesgaard S, Reid M &
Rayman M (2004) Speciation and bioavailability of selenium
in yeast-based intervention agents used in cancer chemopreven-
tion studies. J AOAC Int 87, 225–232.
24. Sloth JJ, Larsen EH, Bugel SH & Moesgaard S (2003) Determi-
nation of total selenium and Se 77 in isotopically enriched
human samples by ICP-dynamic reaction cell-MS. JAAS 18,
317–322.
25. Wheeler CR, Salzman JA, Elsayed NM, Omaye ST & Korte
DW Jr (1990) Automated assays for superoxide dismutase, cat-
alase, glutathione peroxidase, and glutathione reductase activity.
Anal Biochem 184, 193–199.
26. Dragsted LO, Pedersen A, Hermetter A, Basu S, Hansen M,
Haren GR, Kall M, Breinholt V, Castenmiller JJ, Stagsted J,
Jacobsen J, Skibsted L, Rasmussen SE, Loft S & Sandstro¨m
B (2004) The 6-a-day study: effects of fruit and vegetables on
markers of oxidative stress and antioxidative defense in healthy
nonsmokers. Am J Clin Nutr 79, 1060–1072.
27. Alfthan G, Aro A, Arvilommi H & Huttunen JK (1991) Sel-
enium metabolism and platelet glutathione peroxidase activity
in healthy Finnish men: effects of selenium yeast, selenite,
and selenate. Am J Clin Nutr 53, 120–125.
28. Thomson CD, Robinson MF, Butler JA & Whanger PD (1993)
Long-term supplementation with selenate and selenomethio-
nine: selenium and glutathione peroxidase (EC 1.11.1.9) in
blood components of New Zealand women. Br J Nutr 69,
577–588.
29. Levander OA, Alfthan G, Arvilommi H, Gref CG, Huttunen JK,
Kataja M, Koivistoinen P & Pikkarainen J (1983) Bioavailabil-
ity of selenium to Finnish men as assessed by platelet gluta-
thione peroxidase activity and other blood parameters. Am J
Clin Nutr 37, 887–897.
30. Ne`ve J (1995) Human selenium supplementation as assessed by
changes in blood selenium concentration and glutathione per-
oxidase activity. J Trace Elem Med Biol 9, 65–73.
31. Ne`ve J, Vertongen F & Capel P (1988) Selenium supplemen-
tation in healthy Belgian adults: response in platelet glutathione
peroxidase activity and other blood indices. Am J Clin Nutr 48,
139–143.
32. Brown KM, Pickard K, Nicol F, Beckett GJ, Duthie GG &
Arthur JR (2000) Effects of organic and inorganic selenium sup-
plementation on selenoenzyme activity in blood lymphoctyes,
granulocytes, platelets and erythrocytes. Clin Sci (Lond) 98,
593–599.
33. Bukkens SG, de Vos N, Kok FJ, Schouten EG, de Bruijn AM
& Hofman A (1990) Selenium status and cardiovascular
risk factors in healthy Dutch subjects. J Am Coll Nutr 9,
128–135.
34. Ravn-Haren G, Olsen A, Tjonneland A, Dragsted LO, Nexo
BA, Wallin H, Overvad K, Raaschou-Nielsen O & Vogel U
(2006) Associations between GPX1 Pro198Leu polymorphism,
Selenium and oxidative defence 1197
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
http://dx.doi.org/10.1017/S0007114507882948
Downloaded from https:/www.cambridge.org/core. Open University Libraryy, on 09 Jan 2017 at 17:33:09, subject to the Cambridge Core terms of use, available at https:/www.cambridge.org/core/terms.
erythrocyte GPX activity, alcohol consumption and breast
cancer risk in a prospective cohort study. Carcinogenesis 27,
820–825.
35. Tsuchiya Y, Nakajima M, Itoh S, Iwanari M & Yokoi T (2003)
Expression of aryl hydrocarbon receptor repressor in normal
human tissues and inducibility by polycyclic aromatic hydrocar-
bons in human tumor-derived cell lines. Toxicol Sci 72,
253–259.
36. Carlsen H, Myhrstad MC, Thoresen M, Moskaug JO &
Blomhoff R (2003) Berry intake increases the activity of the
g-glutamylcysteine synthetase promoter in transgenic reporter
mice. J Nutr 133, 2137–2140.
37. Whitney AR, Diehn M, Popper SJ, Alizadeh AA, Boldrick JC,
Relman DA & Brown PO (2003) Individuality and variation
in gene expression patterns in human blood. Proc Natl Acad
Sci U S A 100, 1896–1901.
38. Finnstrom N, Thorn M, Loof L & Rane A (2001) Independent
patterns of cytochrome P450 gene expression in liver and
blood in patients with suspected liver disease. Eur J Clin Phar-
macol 57, 403–409.
39. Raucy JL, Schultz ED, Wester MR, Arora S, Johnston DE, Omdahl
JL & Carpenter SP (1997) Human lymphocyte cytochrome P450
2E1, a putative marker for alcohol-mediated changes in hepatic
chlorzoxazone activity. Drug Metab Dispos 25, 1429–1435.
G. Ravn-Haren et al.1198
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
http://dx.doi.org/10.1017/S0007114507882948
Downloaded from https:/www.cambridge.org/core. Open University Libraryy, on 09 Jan 2017 at 17:33:09, subject to the Cambridge Core terms of use, available at https:/www.cambridge.org/core/terms.
